(Q45240887)

English

Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

based on heuristic

inferred from title

author name string

Ji Eun Han

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Seo Ri Wui

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Shin Ae Park

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Na Gyong Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Kwang Sung Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Yang Je Cho

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Hyoung Jin Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Hong-Jin Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

4127-4134

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Classification of papillomaviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

The causal relation between human papillomavirus and cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil HPV vaccine in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Optimizing the secondary structure of human papillomavirus type 16 L1 mRNA enhances L1 protein expression in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

A method for removing contaminating protein during purification of human papillomavirus type 18 L1 protein from Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Efficient intracellular assembly of papillomaviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

The interface between innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Structure of the monophosphoryl lipid A moiety obtained from the lipopolysaccharide of Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Detoxification of endotoxin by aluminum hydroxide adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.079

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.04.079

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45240887&oldid=2070991253"